Navigation Links
NYU Cancer Institute researcher among first NIH EUREKA award recipients
Date:9/3/2008

New York City, NY September 3, 2008 - The National Institutes of Health (NIH) has awarded $42.2 million to fund 38 exceptionally innovative research projects that could have an extraordinarily significant impact on many areas of science. The grants, from a new program called EUREKA (for Exceptional, Unconventional Research Enabling Knowledge Acceleration), targets investigators who are testing novel, unconventional hypotheses or are pursuing major methodological or technical advances. Eureka researchers will receive direct costs of approximately $200,000 per year for up to four years.

Michelle Krogsgaard, Ph.D, assistant professor of pathology at the NYU Cancer Institute, is the first NYU School of Medicine recipient of the EUREKA award. In 2006, Dr. Krogsgaard joined NYU and her work has focused on the different signaling methods T-cells use in the contexts of cancer and autoimmune disease. The EUREKA award will allow Dr. Krogsgaard to explore the complex molecular mechanisms that govern the training and activation of immune cells; specifically, how intracellular signals are generated in T-cells, currently an immunological black box. Dr. Krogsgaard practices an interdisciplinary approach to her research, which incorporates cellular, chemical and structural biology techniques. Through this fresh perspective and multidisciplinary approach, Dr. Krogsgaard aims to build on her previous training to initiate a novel and risky approach to study mechanisms of T-cell signaling and to bolster her controversial hypothesis that structural changes in the receptor complex are important for T-cell signaling. This award will give her the freedom to explore innovative techniques and interdisciplinary approaches that would not be supported by an R01 award.

Using a combination of novel imaging and biophysical techniques, Dr. Krogsgaard investigates how one can manipulate signaling mechanisms in T-cells which could enhance the immune response in patients with HIV or cancer or diminish T-cell activation in patients with autoimmune disease.


'/>"/>

Contact: Jennifer Berman
Jennifer.Berman@nyumc.org
212-404-3555
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Related biology news :

1. Blood fingerprints for cancer
2. Height linked to risk of prostate cancer development and progression
3. TGen and Washington University researchers discover new approach to treating endometrial cancer
4. Landmark study opens door to new cancer, aging treatments
5. Growth factor predicts poor outcome in breast cancer
6. Researchers discover atomic bomb effect results in adult-onset thyroid cancer
7. AACR hosts Molecular Diagnostics in Cancer Therapeutic Development Meeting
8. Normalizing tumor vessels to improve cancer therapy
9. CSHL scientists identify new drug target against virulent type of breast cancer
10. Gene therapy anti-cancer research featured in Scientific American
11. Dense tissue promotes aggressive cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... May 23, 2017  Hunova, the first robotic gym for the rehabilitation ... officially launched in Genoa, Italy . The first 30 ... and the USA . The technology was developed and ... by the IIT spin-off Movendo Technology thanks to a 10 million euro ... Release, please click: ...
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
Breaking Biology News(10 mins):
(Date:6/22/2017)... ... June 22, 2017 , ... For the months of May ... Spotlight series on “Cell Therapy Regulation” for its regenerative medicine followship. ... the unique regulatory challenges of stem cell medical research. , Stem cell clinical ...
(Date:6/22/2017)... ... 2017 , ... Charm Sciences, Inc. is pleased to announce that its Charm ... appropriate as a screening test at dairies and farms for raw commingled cow milk. ... Charm EZ Lite system. These systems are a combination incubator and reader in one. ...
(Date:6/20/2017)...  Kibow Biotech Inc., a pioneer in developing "Enteric ... a new patent covering a unique method for preventing ... and Trademark Office on May 23 rd 2017. ... Bio award in 2014 in San Diego, ... to chronic disease. Renadyl™, the first and only dietary ...
(Date:6/19/2017)... ... 19, 2017 , ... As Vice President, Product Services, Mr. ... implementation, support, and client process and SOP development. , Mr. Guinter brings a ... roles for service providers and top-tier pharmaceuticals, and as an independent consultant supported ...
Breaking Biology Technology: